Literature DB >> 22562502

Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo.

H K Brown1, P D Ottewell, C A Evans, I Holen.   

Abstract

Bone metastasis is a common incurable complication of breast cancer affecting around 70% of patients with advanced disease. In order to improve outcomes for these patients, the cellular and molecular mechanisms underlying bone metastasis need to be established. The majority of studies to date have focused on end-stage disease and little is known about the events taking place following initial tumour cell colonisation of bone. Here we report the results of a longitudinal study that provides detailed analysis of the spatial and temporal relationship between bone and cancer cells during progression of bone metastasis. Tumour growth in bone was initiated by intra-cardiac inoculation of MDA-MB-231-GFP breast cancer cells in immunocompromised mice. Differentiating between areas of bone in direct contact with the tumour and areas distal to the cancer cells but within the tumour bearing bone, we performed comprehensive analyses of the number and distribution of osteoclasts and osteoblasts. Tumour colonies were detectable in bone from day 10, while reduced trabecular bone volume was apparent from day 19 onwards. Cancer-induced changes in osteoblast and osteoclast numbers differed substantially depending on whether or not the cells were in direct contact with the tumour. Compared to naïve controls, areas of bone in direct contact with the tumour had significantly reduced osteoblast but increased osteoclast numbers, whereas the reverse was found in distal areas. Our data demonstrate that tumour cells induce substantial changes in the bone microenvironment prior to the appearance of bone lesions, suggesting that early therapeutic intervention may be required to oppose the tumour-induced changes to the microenvironment und thus tumour progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562502     DOI: 10.1007/s10585-012-9481-5

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  32 in total

1.  Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.

Authors:  F P Coxon; M H Helfrich; R Van't Hof; S Sebti; S H Ralston; A Hamilton; M J Rogers
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

2.  Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.

Authors:  D R Clohisy; D Palkert; M L Ramnaraine; I Pekurovsky; M J Oursler
Journal:  J Orthop Res       Date:  1996-05       Impact factor: 3.494

3.  Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

Authors:  Eva Corey; Lisha G Brown; Janna E Quinn; Martin Poot; Martine P Roudier; Celestia S Higano; Robert L Vessella
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

4.  Kinetics of metastatic breast cancer cell trafficking in bone.

Authors:  Pushkar A Phadke; Robyn R Mercer; John F Harms; Yujiang Jia; Andra R Frost; Jennifer L Jewell; Karen M Bussard; Shakira Nelson; Cynthia Moore; John C Kappes; Carol V Gay; Andrea M Mastro; Danny R Welch
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

5.  Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis.

Authors:  Sindhu T Mohanty; Lucksy Kottam; Alessandra Gambardella; Martin J Nicklin; Les Coulton; David Hughes; Anthony G Wilson; Peter I Croucher; Ilaria Bellantuono
Journal:  Arthritis Res Ther       Date:  2010-07-22       Impact factor: 5.156

6.  Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Authors:  Penelope D Ottewell; Hannu Mönkkönen; Mark Jones; Diane V Lefley; Robert E Coleman; Ingunn Holen
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

7.  RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.

Authors:  Allison P Armstrong; Robert E Miller; Jon C Jones; Jian Zhang; Evan T Keller; William C Dougall
Journal:  Prostate       Date:  2008-01-01       Impact factor: 4.104

8.  Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts.

Authors:  D R Clohisy; C M Ogilvie; R J Carpenter; M L Ramnaraine
Journal:  J Orthop Res       Date:  1996-01       Impact factor: 3.494

9.  Breast-cancer adjuvant therapy with zoledronic acid.

Authors:  Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell
Journal:  N Engl J Med       Date:  2011-09-25       Impact factor: 91.245

10.  Pre-osteoblastic MC3T3-E1 cells promote breast cancer growth in bone in a murine xenograft model.

Authors:  Thomas M Bodenstine; Benjamin H Beck; Xuemei Cao; Leah M Cook; Aimen Ismail; Should J Kent Powers; J Kent Powers; Andrea M Mastro; Danny R Welch
Journal:  Chin J Cancer       Date:  2011-03
View more
  20 in total

1.  Three-Dimensional Mechanical Loading Modulates the Osteogenic Response of Mesenchymal Stem Cells to Tumor-Derived Soluble Signals.

Authors:  Maureen E Lynch; Aaron E Chiou; Min Joon Lee; Stephen C Marcott; Praveen V Polamraju; Yeonkyung Lee; Claudia Fischbach
Journal:  Tissue Eng Part A       Date:  2016-08-01       Impact factor: 3.845

Review 2.  Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.

Authors:  Stephanie Strobl; Kerstin Wimmer; Ruth Exner; Yelena Devyatko; Michael Bolliger; Florian Fitzal; Michael Gnant
Journal:  Curr Treat Options Oncol       Date:  2018-03-12

3.  Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response.

Authors:  Mehdi Najar; Hussein Fayyad-Kazan; Wissam H Faour; Bassam Badran; Fabrice Journe; Laurence Lagneaux
Journal:  Inflamm Res       Date:  2016-10-25       Impact factor: 4.575

4.  Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions.

Authors:  I Holen; F Nutter; J M Wilkinson; C A Evans; P Avgoustou; Penelope D Ottewell
Journal:  Clin Exp Metastasis       Date:  2015-08-01       Impact factor: 5.150

Review 5.  Targeting RANKL in metastasis.

Authors:  William C Dougall; Ingunn Holen; Eva González Suárez
Journal:  Bonekey Rep       Date:  2014-04-09

6.  Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo.

Authors:  Marie-Therese Haider; Keith D Hunter; Simon P Robinson; Timothy J Graham; Eva Corey; T Neil Dear; Russell Hughes; Nicola J Brown; Ingunn Holen
Journal:  Bone       Date:  2015-08-14       Impact factor: 4.398

7.  The role of osteoblasts in bone metastasis.

Authors:  Penelope D Ottewell
Journal:  J Bone Oncol       Date:  2016-04-13       Impact factor: 4.072

8.  Modeling bystander effects that cause growth delay of breast cancer xenografts in bone marrow of mice treated with radium-223.

Authors:  Didier A Rajon; Brian S Canter; Calvin N Leung; Tom A Bäck; J Christopher Fritton; Edouard I Azzam; Roger W Howell
Journal:  Int J Radiat Biol       Date:  2021-07-26       Impact factor: 3.352

9.  Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.

Authors:  Laura S Gregory; Wilson Choi; Leslie Burke; Judith A Clements
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

10.  Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.

Authors:  Marie-Therese Haider; Ingunn Holen; T Neil Dear; Keith Hunter; Hannah K Brown
Journal:  Bone       Date:  2014-06-24       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.